Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies.
Renneville A, Gasser JA, Grinshpun DE, Jean Beltran PM, Udeshi ND, Matyskiela ME, Clayton T, McConkey M, Viswanathan K, Tepper A, Guirguis AA, Sellar RS, Cotteret S, Marzac C, Saada V, De Botton S, Kiladjian JJ, Cayuela JM, Rolfe M, Chamberlain PP, Carr SA, Ebert BL.
Renneville A, et al. Among authors: chamberlain pp.
Blood Cancer Discov. 2021 May;2(3):250-265. doi: 10.1158/2643-3230.BCD-20-0105. Epub 2021 Mar 10.
Blood Cancer Discov. 2021.
PMID: 34027417
Free PMC article.